What You Should Know:
- Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine.
- Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine.
Syapse, a San
Francisco, CA-based provider of precision oncology
solutions announced $30
Read More
2020 MedTech Breakthrough Award Winners Announced
What You Should Know:
- MedTech Breakthrough announces 2020 MedTech Breakthrough Award Winners that recognizes the top companies, people, platforms, and products in the health, fitness, and medical technology industries today.
- The 2020 MedTech Breakthrough Awards program is open to all individuals, companies, and organizations involved in producing digital health and medical technology products and services.
MedTech
Breakthrough, a market intelligence organization that
Read More
In-Depth: 32 FDA-Approved COVID-19 Testing Kits
What You Should Know:
- In-depth look list of FDA-approved COVID-19 test kits
The U.S. Food and Drug Administration (FDA) offers emergency use authorizations (EUAs) for unapproved products or new uses for approved items in urgent situations where no suitable alternatives exist. Dozens of companies have sought and received EUAs for their testing kits that screen for SARS-CoV-2 — more commonly referred to as COVID-19 or the novel coronavirus.
The FDA makes a
Read More
TeraRecon Acquired by SymphonyAI: What is the Impact for Medical Imaging Market?
On the 4th March 2020, TeraRecon announced it had signed an agreement to be acquired by the SymphonyAI Group. Here are the facts of the deal, followed by our take on the potential impact on the medical imaging market:
- The terms of the deal were not disclosed and TeraRecon will continue to operate business as usual. However, it will benefit from greater financial backing and the synergistic technologies from other companies in the Group’s portfolio.
- TeraRecon is an Advanced
Read More
Tempus, Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).The Cancer Genome Atlas (TCGA) Project BackgroundThere are 230 distinct investigators that contributed
Read More
HealthQuest Capital Closes $440M Fund to Invest in Innovative Growth-Stage Companies
HealthQuest Capital, a Silicon Valley-based growth capital firm has closed a $440 million fund to invest growth-stage companies delivering innovation across all sectors of the healthcare industry to improve patient outcomes, enhance efficiency and reduce costs. Fund III was oversubscribed and closed at a hard cap. Target markets for Fund III include growth- and commercial-stage companies focusing on medical technologies, diagnostics, digital health, and innovative services.HealthQuest Capital
Read More
Roche Integrates Insulin Data from Novo Nordisk with Diabetes Management Solutions
Roche has signed a development and collaboration agreement with Novo Nordisk, a leader in innovating the therapy of diabetes and obesity. Under the terms of the development and collaboration agreement, the partners will integrate insulin data from Novo Nordisk's connected pen to Roche's open ecosystem, synchronizing with its suite of digital diabetes management solutions including mySugr.People with diabetes spend an average of one hour per day on self-care and have to make up to 50 therapy
Read More
Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine
Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer.Foundation Medicine, based in Cambridge, Massachusetts, is a market leading molecular information company dedicated to a transformation in
Read More
Roche Acquires Oncology EHR Startup Flatiron Health for $1.9B
Roche has reached an agreement to acquire Flatiron Health, a NYC-based oncology EHR startup focused on accelerating cancer research and improving patient care for $1.9B. Under terms of the acquisition, Flatiron Health will continue its current business model, network of partnerships and overall objectives. The integrity of segregated patient protected health information will be preserved, as will dedicated sales and marketing, provider-facing and life science business activities. In addition,
Read More
Accenture, Roche Partner on Digital Health Integration for Tumor Board Solution
Accenture and Roche are teaming up on a new collaboration aimed at improving how oncology teams prepare for, conduct and document clinical treatment decisions for cancer patients in hospitals. Under the terms of the multi-year agreement, Accenture will provide digital health data integration services to Roche’s NAVIFY Tumor Board solution – fostering more efficient collaboration, reducing errors and giving care teams more time to evaluate individual patient cases.What Is A Tumor Board? A tumor
Read More
